Literature DB >> 22308483

Serotype-independent pneumococcal experimental vaccines that induce cellular as well as humoral immunity.

Richard Malley1, Porter W Anderson.   

Abstract

For prevention of Streptococcus pneumoniae (pneumococcus) infections in infancy, protein-conjugated capsular polysaccharide vaccines provide serotype-specific, antibody-mediated immunity but do not cover all of the 90+ capsule serotypes. Therefore, microbiologists have sought protective noncapsular antigens common to all strains. Alternatively, we investigated killed cells of a noncapsulated strain, which expose many such common antigens. Given to mice intranasally, this vaccine elicits antibody-independent, CD4+ T lymphocyte-dependent accelerated clearance of pneumococci of various serotypes from the nasopharynx mediated by the cytokine IL-17A. Such immunity may reproduce the natural resistance that develops in infants before capsular antibodies arise. Given by injection, the killed cell vaccine induces bifunctional immunity: plasma antibodies protective against fatal pneumonia challenge, as well as IL-17A-mediated nasopharyngeal clearance. Human testing of this inexpensive candidate vaccine by intramuscular injection is planned. Bacterial cellular vaccines are complex--a challenge for reproducibility. However, when several known protective antigens were deleted, the killed pneumococcal vaccine was still protective. This antigenic redundancy may prevent vaccine escape variants by recombinational loss, which is frequent in pneumococcus. Biochemically defined immunogens with bifunctional activity have also been devised. These immunogens are three-component conjugates in which cell wall teichoic acid (a common antigen capable of T cell activation) is coupled to a genetic fusion of two common pneumococcal proteins: a protective surface antigen and a derivative of pneumolysin, which provides TLR4 agonist activity and induces antitoxic immunity. Such constructs induce accelerated clearance when given intranasally and induce both immune mechanisms when injected. The defined composition permits analysis of structure-function activity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22308483      PMCID: PMC3309758          DOI: 10.1073/pnas.1121383109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  72 in total

1.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Multiserotype protection of mice against pneumococcal colonization of the nasopharynx and middle ear by killed nonencapsulated cells given intranasally with a nontoxic adjuvant.

Authors:  Richard Malley; Sarah C Morse; Luciana C C Leite; Ana Paula Mattos Areas; Paulo Lee Ho; Flavia S Kubrusly; Igor C Almeida; Porter Anderson
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

3.  Intranasal immunization with killed unencapsulated whole cells prevents colonization and invasive disease by capsulated pneumococci.

Authors:  R Malley; M Lipsitch; A Stack; R Saladino; G Fleisher; S Pelton; C Thompson; D Briles; P Anderson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  PneumococcaL meningitis in french children before and after the introduction of pneumococcal conjugate vaccine.

Authors:  Corinne Levy; Emmanuelle Varon; Edouard Bingen; Aurélie Lécuyer; Michel Boucherat; Robert Cohen
Journal:  Pediatr Infect Dis J       Date:  2011-02       Impact factor: 2.129

5.  GMP-grade pneumococcal whole-cell vaccine injected subcutaneously protects mice from nasopharyngeal colonization and fatal aspiration-sepsis.

Authors:  Ying-Jie Lu; Luciana Leite; Viviane Maimoni Gonçalves; Waldely de Oliveira Dias; Celia Liberman; Fernando Fratelli; Mark Alderson; Andrea Tate; Jean-François Maisonneuve; George Robertson; Rita Graca; Sabina Sayeed; Claudette M Thompson; Porter Anderson; Richard Malley
Journal:  Vaccine       Date:  2010-09-19       Impact factor: 3.641

6.  Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules.

Authors:  G S Nabors; P A Braun; D J Herrmann; M L Heise; D J Pyle; S Gravenstein; M Schilling; L M Ferguson; S K Hollingshead; D E Briles; R S Becker
Journal:  Vaccine       Date:  2000-03-06       Impact factor: 3.641

7.  CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.

Authors:  O T Avery; W F Goebel
Journal:  J Exp Med       Date:  1929-09-30       Impact factor: 14.307

8.  The induction of meningeal inflammation by components of the pneumococcal cell wall.

Authors:  E Tuomanen; H Liu; B Hengstler; O Zak; A Tomasz
Journal:  J Infect Dis       Date:  1985-05       Impact factor: 5.226

9.  Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection.

Authors:  Richard Malley; Philipp Henneke; Sarah C Morse; Michael J Cieslewicz; Marc Lipsitch; Claudette M Thompson; Evelyn Kurt-Jones; James C Paton; Michael R Wessels; Douglas T Golenbock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-04       Impact factor: 11.205

10.  Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide.

Authors:  Ying-Jie Lu; Sophie Forte; Claudette M Thompson; Porter W Anderson; Richard Malley
Journal:  Infect Immun       Date:  2009-03-02       Impact factor: 3.441

View more
  39 in total

1.  T(H)17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins.

Authors:  K Moffitt; A Howard; S Martin; E Cheung; M Herd; A Basset; R Malley
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

Review 2.  Helper T-cell type 17 cytokines and immunity in the lung.

Authors:  Jay K Kolls
Journal:  Ann Am Thorac Soc       Date:  2014-12

3.  Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Authors:  Kirsten Kuipers; Wouter S P Jong; Christa E van der Gaast-de Jongh; Diane Houben; Fred van Opzeeland; Elles Simonetti; Saskia van Selm; Ronald de Groot; Marije I Koenders; Taj Azarian; Elder Pupo; Peter van der Ley; Jeroen D Langereis; Aldert Zomer; Joen Luirink; Marien I de Jonge
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

Review 4.  Updates on T helper type 17 immunity in respiratory disease.

Authors:  Naoki Iwanaga; Jay K Kolls
Journal:  Immunology       Date:  2018-10-24       Impact factor: 7.397

Review 5.  Dynamics of lung defense in pneumonia: resistance, resilience, and remodeling.

Authors:  Lee J Quinton; Joseph P Mizgerd
Journal:  Annu Rev Physiol       Date:  2014-08-13       Impact factor: 19.318

6.  Toll-like receptor 2-dependent protection against pneumococcal carriage by immunization with lipidated pneumococcal proteins.

Authors:  Kristin Moffitt; Mojca Skoberne; Angela Howard; L Cristina Gavrilescu; Todd Gierahn; Scott Munzer; Bharat Dixit; Paul Giannasca; Jessica Baker Flechtner; Richard Malley
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

Review 7.  Host defenses against bacterial lower respiratory tract infection.

Authors:  Taylor Eddens; Jay K Kolls
Journal:  Curr Opin Immunol       Date:  2012-07-25       Impact factor: 7.486

Review 8.  Prevention and Control of Childhood Pneumonia and Diarrhea.

Authors:  Daniel T Leung; Mohammod J Chisti; Andrew T Pavia
Journal:  Pediatr Clin North Am       Date:  2016-02       Impact factor: 3.278

9.  HIV-induced immunosuppression is associated with colonization of the proximal gut by environmental bacteria.

Authors:  Liying Yang; Michael A Poles; Gene S Fisch; Yingfei Ma; Carlos Nossa; Joan A Phelan; Zhiheng Pei
Journal:  AIDS       Date:  2016-01-02       Impact factor: 4.177

10.  Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.

Authors:  Karlis Pauksens; Anna C Nilsson; Magalie Caubet; Thierry G Pascal; Pascale Van Belle; Jan T Poolman; Pierre G Vandepapelière; Vincent Verlant; Peter E Vink
Journal:  Clin Vaccine Immunol       Date:  2014-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.